brequinar

Also Known As:

6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid; 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid sodium; DuP 785; DuP-785; NSC 368390; NSC-368390; brequinar potassium; brequinar sodium; brequinar sodium salt

Networked: 65 relevant articles (5 outcomes, 18 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Biphenyl Compounds: 7
        brequinar: 65
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinaldines
        brequinar: 65

Experts

1.	Cuthbertson, Christine R: 3 articles (12/2020 - 10/2017)
2.	Madak, Joseph T: 3 articles (12/2020 - 10/2017)
3.	Neamati, Nouri: 3 articles (12/2020 - 10/2017)
4.	Dorasamy, Mathura Subangari: 2 articles (02/2019 - 01/2017)
5.	Nellore, Kavitha: 2 articles (02/2019 - 01/2017)
6.	Wong, Pooi-Fong: 2 articles (02/2019 - 01/2017)
7.	Showalter, Hollis D: 2 articles (01/2019 - 10/2017)
8.	Arabyan, Erik: 1 article (01/2022)
9.	Batinic, Drago: 1 article (01/2022)
10.	Batinic, Josip: 1 article (01/2022)

Related Diseases

1.	Neoplasms (Cancer) 12/11/2020 - "Therefore, a combination of brequinar and ENT inhibitors presents a potential anti-cancer strategy in select tumors." 07/03/2014 - "Furthermore, several other cancer cell lines, LNCaP, MCF-7 and HT-29 were also shown to be sensitized to TRAIL by brequinar. " 01/01/1994 - "Protein binding of brequinar in the plasma of healthy donors and cancer patients and analysis of the relationship between protein binding and pharmacokinetics in cancer patients." 02/01/1993 - "We conclude that, at this dose and schedule, brequinar does not have sufficient activity in these gastrointestinal malignancies to warrant further evaluation." 01/01/1992 - "Brequinar is such an inhibitor that has little clinical anti-tumor effect when used alone. "
2.	Colorectal Neoplasms (Colorectal Cancer) 01/01/1990 - "Phase II trial with Brequinar (DUP-785, NSC 368390) in patients with metastatic colorectal cancer: a study of the Early Clinical Trials Group of the EORTC." 01/01/1987 - "Among 22 investigational compounds, currently being investigated in phase I or early phase II clinical trials, we found that trimetrexate, DUP-785, didemnin-B, and flavone-8-acetic acid might be effective for treatment of patients with colorectal cancer." 01/01/1988 - "Our results suggest that trimetrexate, DUP-785, didemnin B, and flavone-8-acetic acid may be clinically effective for the treatment of colorectal cancer."
3.	Neuroblastoma 01/01/2022 - "Furthermore, brequinar treatment was shown to reduce the expression of MYC targets in 3 neuroblastoma models in vivo. " 01/01/2022 - "A combination of brequinar and temozolomide was curative in the majority of transgenic TH-MYCN neuroblastoma mice, indicating a highly active clinical combination therapy. " 01/01/2022 - "In xenograft and transgenic neuroblastoma mouse models treated with the DHODH inhibitor brequinar, tumor growth was dramatically reduced, and survival was extended. "
4.	Melanoma (Melanoma, Malignant) 09/01/1992 - "Multicenter phase II trial of brequinar sodium in patients with advanced melanoma." 09/01/1992 - "We conclude that, at this dose and schedule, brequinar has no activity in advanced melanoma." 09/01/1992 - "Seventeen patients with advanced melanoma and no prior exposure to chemotherapy were treated with brequinar sodium as first-line chemotherapy. " 01/01/1987 - "First, we studied growth inhibition by DUP-785 in L1210 leukemia cells and M5 melanoma cells. " 02/01/2019 - "Synergistic inhibition of melanoma xenografts by Brequinar sodium and Doxorubicin."
5.	Breast Neoplasms (Breast Cancer) 12/01/1993 - "Multicenter phase II study of brequinar sodium in patients with advanced breast cancer." 12/01/1993 - "We conclude that, at this dose and schedule, brequinar has only modest activity in patients with advanced breast cancer." 12/01/1993 - "In this study, 34 patients with advanced breast cancer were treated with brequinar sodium: 75% of the patients were postmenopausal, and 94% had received chemotherapy previously; 50% had previously received an anthracycline-containing regimen. " 12/01/2022 - "Using mouse models of mammary cancer that elicit robust MDSC responses, we demonstrated that the DHODH inhibitor brequinar (a) suppressed MDSC production from early-stage myeloid progenitors, which was accompanied by enhanced myeloid maturation; (b) augmented the antitumor and antimetastatic activities of programmed cell death 1-based (PD-1-based) ICI therapy in ICI-resistant mammary cancer models; and (c) acted in concert with PD-1 blockade through modulation of MDSC and CD8+ T cell responses. " 12/01/2022 - "While brequinar (BRQ), an inhibitor of dihydroorotate dehydrogenase, shows cytotoxicity in hematological malignancy, it has not yet been adapted to attenuate MDSCs by augmenting bone marrow progenitors in breast cancer. "

Related Drugs and Biologics

1.	brequinar
2.	Trimetrexate (JB11)
3.	flavone acetic acid
4.	didemnins
5.	Dihydroorotate Dehydrogenase
6.	Proteins (Proteins, Gene)
7.	Blood Proteins (Serum Proteins)
8.	Salts
9.	Antineoplastic Agents (Antineoplastics)
10.	pyrimidine

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Injections
4.	Immunotherapy